The PROTAC (proteolysis-targeting chimera) ARV-825 recruits bromodomain and extraterminal (BET) proteins to the E3 ubiquitin ligase cereblon, leading to degradation of BET proteins, including BRD4. Although the BET-protein inhibitor (BETi) OTX015 caused accumulation of BRD4, treatment with equimolar concentrations of ARV-825 caused sustained and profound depletion (490%) of BRD4 and induced significantly more apoptosis in cultured and patient-derived (PD) CD34+ post-MPN sAML cells, while relatively sparing the CD34+ normal hematopoietic progenitor cells. RNA-Seq, Reverse Phase Protein Array and mass cytometry 'CyTOF' analyses demonstrated that ARV-825 caused greater perturbations in messenger RNA (mRNA) and protein expressions than OTX015 in sAML cells. Specifically, compared with OTX015, ARV-825 treatment caused more robust and sustained depletion of c-Myc, CDK4/6, JAK2, p-STAT3/5, PIM1 and Bcl-xL, while increasing the levels of p21 and p27. Compared with OTX015, PROTAC ARV-771 treatment caused greater reduction in leukemia burden and further improved survival of NSG mice engrafted with luciferaseexpressing HEL92.1.7 cells. Co-treatment with ARV-825 and JAK inhibitor ruxolitinib was synergistically lethal against established and PD CD34+ sAML cells. Notably, ARV-825 induced high levels of apoptosis in the in vitro generated ruxolitinib-persister or ruxolitinib-resistant sAML cells. These findings strongly support the in vivo testing of the BRD4-PROTAC based combinations against post-MPN sAML.
INTRODUCTION
Hematopoietic stem/progenitor cells of BCR-ABL1-negative myeloproliferative neoplasms with myelofibrosis (MPN-MF) exhibit mutations in JAK2, c-MPL or calreticulin (CALR) gene and display constitutive activation of JAK-STAT signaling. 1, 2 In MPN-MF, transformation to AML (sAML) occurs in up to 20% of patients. 3 Ruxolitinib (Rux), a type I, ATP-competitive, dual JAK1/2 inhibitor (JAKi), is currently used as the therapy for MPN-MF. 4, 5 Although treatment with ruxolitinib confers notable clinical benefit in MPN-MF, it exhibits only modest activity and does not significantly impact the clinical outcome in post-MPN sAML. 3, [6] [7] [8] Prolonged exposure to ruxolitinib may also lead to a loss of response, causing the emergence of JAKi-resistant (JIR) sAML cells in patients. 9, 10 Although they lack additional JAK2 mutations, JIR cells exhibit reactivation of JAK-STAT signaling due to trans-phosphorylation of JAK2 by JAK1 or TYK2 tyrosine kinases (TKs). 11 Sequential genomic assessments in pre-and post-sAML transformation have revealed mutations in TET2, ASXL1, IDH1&2, SRSF2, RUNX1, MYC, PTPN11, NRAS, SETBP1 and TP53 genes. 12, 13 Because standard chemotherapy is also relatively ineffective as a therapy for sAML, 3, 7 there is an urgent need to develop novel therapeutics for the treatment of this disease.
BET (bromodomain and extraterminal) family of proteins, including BRD4, are chromatin reader proteins. 14, 15 They possess the N-terminal double tandem bromodomains, which bind to the acetylated lysines on nucleosomal histones and transcription factors. 14, 15 Through their extraterminal (ET) domain in the C-terminus, they interact and recruit co-regulatory chromatinmodifying enzymes, remodeling factors and the mediator elements to the chromatin for regulating gene transcription. 15 The C-terminal domain (CTD) of BRD4 binds to P-TEFb (positive transcription elongation factor b); the heterodimer composed of cyclin dependent kinase 9 (CDK9) and its regulatory subunit cyclin T. 16 The kinase activity of CDK9 in P-TEFb phosphorylates serine 2 in the heptad-repeats in the C-terminal domain (CTD) of RNA pol II (RNAP2), stimulating mRNA transcript elongation at the enhancers and promoters of oncogenes, especially those of c-Myc, Bcl-xL, PIM1 and CDK4/6, that are regulated by clustered or 'super' enhancers and are important for cell growth and survival of sAML cells. [17] [18] [19] [20] An RNAi screen identified BRD4 as an effective and promising target in AML cells. 21 Several structure/activity-based BET protein small-molecule, acetyl-lysine-mimetic inhibitors (BETi) have been developed, including OTX015 and GSK525762. 22, 23 These agents displace BET proteins, along with the co-regulators of transcription chromatin, causing transcriptional repression of BCL2, c-Myc and CDK4/6. 22, 24 Recently, we have demonstrated that treatment with BETi, for example, JQ1 and I-BET151, attenuates the expression of c-Myc, p-STAT5, PIM1 and CDK4/6, inhibits growth and induces apoptosis of cultured and patientderived (PD) CD34+ sAML blast progenitor cells, 25 including those that co-express JAK2-V617F and mutant TP53, for example, HEL92.1.7 and SET2 cells. 25, 26 Co-treatment with BETi and ruxolitinib synergistically induced apoptosis of cultured and PD CD34+ sAML cells. As compared with treatment with vehicle control, or JQ1 or ruxolitinib as single agents, co-treatment with JQ1 and ruxolitinib significantly improved the median survival of the immune-depleted mice engrafted with HEL92.1.7 cells. Despite significant AML activity, BETi treatment leads to BRD4 protein accumulation over time. 27, 28 Together with the reversible nature of the binding of BETi to BET proteins, this may account for suboptimal BETi-mediated transcriptional repression of MYC, Bcl-xL, PIM1, CDK4/6 and other oncoproteins, as well as reduced apoptosis. 26, 27 To circumvent this limitation, hetero-bifunctional PROTACs (proteolysis-targeting chimera) with two recruiting ligands connected via a linker have been designed. [27] [28] [29] In the BET-PROTAC ARV-825 (Arvinas, Inc.), one ligand is the BRD4 binding moiety (OTX015) while the other moiety (pomalidomide) specifically hijacks and recruits the E3 ubiquitin ligase cereblon to polyubiquitylate and proteasomally degrade BETPs including BRD4. 27 Unlike BETis, the BET-PROTAC can potentially act catalytically and facilitate multiple rounds of sub-stoichiometric catalysis, [27] [28] [29] leading to efficient and prolonged depletion of the levels of BET proteins, including BRD4 (490%) in the sAML cells. Therefore, we compared the anti-sAML activity of ARV-825 with the BETi OTX015, against cultured and PD CD34+ sAML cells. Our findings demonstrate that at equimolar concentrations ARV-825 is significantly more potent than OTX015 in inducing apoptosis of sAML cells sensitive or resistant to ruxolitinib, while relatively sparing the CD34+ normal hematopoietic progenitor cells. Notably, although OTX015 treatment increased BRD4 levels, ARV-825 markedly depleted BRD4, as well as caused more robust attenuation of the levels of c-Myc, p-STAT5, Bcl-xL, PIM1 and CDK4/6, exerting synergistic lethality with ruxolitinib against sAML cells.
MATERIALS AND METHODS

Cell lines and PD post-MPN-MF sAML cells
Post-MPN sAML SET2 and HEL92.1.7 (HEL) cells expressing mutant JAK2-V617F and TP53 were obtained from the DSMZ (Braunschweig, Germany) and ATCC (Manassas, VA, USA), respectively. UKE1 cells were obtained and characterized as previously described. 9 All experiments with the cell lines were performed within 6 months after thawing or obtaining from ATCC or DSMZ. HEL92.1.7 ruxolitinib-persister cells were generated by exposing the cells to 1.0 μm of ruxolitinib for 48 h. Dead cells were removed by Ficoll-Hypaque density gradient centrifugation. Live cells were expanded in drug-free media and then treated with additional rounds of identical ruxolitinib treatments and recovery. After this, the viable, expanded cells were treated with the drugs for the described studies. The PD peripheral blood and/or bone marrow aspirate samples were obtained with informed consent from patients with sAML and processed to separate the mononuclear and CD34+ sAML blast progenitor cells, as previously described. 9 RNA purification, sequencing and quantitative PCR of sAML cells The methods followed for RNA purification, sequencing (NGS) and qPCR analyses of RNA from the cultured and PD CD34+ sAML cells were as previously described 30 and detailed in the Supplementary Methods. RNA-Seq data are deposited in GEO under accession number GSE93578.
Assessment of apoptosis by annexin-V staining
Untreated or drug-treated cells were stained with annexin-V (Pharmingen, San Diego, CA, USA) and TO-PRO-3 iodide (Life Technologies, Carlsbad, CA, USA) and the percentages of apoptotic cells were determined by flow cytometry as previously described. 31 For PD sAML cells, loss of viability following drug treatment was determined by propidium iodide staining and flow cytometry, as previously described. 32 Western blot analysis, reverse-phase protein array and single-cell mass cytometry analysis
The methods followed for performing the western blot, reverse-phase protein array and single-cell mass cytometry analyses were as previously described, [31] [32] [33] [34] [35] and are detailed in the Supplementary Methods.
In vivo sAML mouse model Luciferase-expressing sAML HEL92.1.7 cells were engrafted into NSG mice and treated with OTX015 or ARV-771 as described in the Supplementary Methods. The survival of the mice is represented by a Kaplan-Meier plot.
Statistical analysis
Significant differences between values obtained in a population of sAML cells treated with different experimental conditions were determined using a one-tailed, unpaired t-test. P-values less than 0.05 were assigned significance.
RESULTS
Compared with BETi, treatment with BET-PROTAC causes profound and sustained depletion of BRD4 in sAML cells
We first compared the effect of treatment with the BETi OTX015 versus ARV-825 on the levels of BET proteins BRD4 and BRD2 in sAML SET2 cells. As has been previously demonstrated in Burkitt's lymphoma cells lines, 27 in contrast to OTX015, which caused accumulation and increased levels of BRD4 protein, treatment with ARV-825 caused marked depletion of the levels of BRD4 and BRD2 in sAML SET2 cells (Figures 1a and b ). The BETi JQ1 treatment also induced BRD4 levels in sAML HEL92.1.7 and SET2 cells (Supplementary Figure S1A) . Confocal immunofluorescent microscopy also demonstrated that treatment with ARV-825 significantly depleted the nuclear expression of BRD4 in sAML cells, while OTX015 treatment increased BRD4 nuclear expression ( Figures 1c and d ). Although treatment with pomalidomide had no effect on the levels of BRD4 and BRD2, co-treatment with pomalidomide significantly restored the ARV-825-mediated depletion of BRD4 and BRD2 levels (Supplementary Figures S1B and C). We also assessed BRD4 and BRD2 levels in sAML cells treated with equimolar (1.0 μm) concentrations of ARV-825 or OTX015 for 24 h, followed by compound washout, replenishment of the cells with fresh medium and incubating them for an additional 24 h in drug-free medium. As shown in Figure 1b , compared with the high expression of BRD4 and BRD2 in the OTX015-treated post-washout cells, prior treatment with ARV-825 caused a sustained depletion of BRD4 and BRD2 in the postwashout cells. This implies that the sustained nuclear depletion of the levels of BRD4 mediated by exposure to ARV-825 would undermine the transcription-promoting effects of BRD4 at the enhancers and promoters.
BET-PROTAC is more potent than BETi in inducing apoptosis of post-MPN cultured and PD CD34+ sAML cells We next compared the effects of BET-PROTAC ARV-825 versus the BETi OTX015 in inducing apoptosis of cultured sAML SET2 and UKE1 cells. At equimolar concentrations, ARV-825 dose-dependently induced significantly more apoptosis than OTX015 in SET2 (ARV-825 IC 50 = 14.5 ± 0.2 nm; OTX015 IC 50 = 256 ± 21 nm) and UKE1 (ARV-825 IC 50 = 256 ± 12.45 nm; OTX015 IC 50 4500 nm) cells (Figures 2a and b ). SET2 cells were more sensitive than UKE1 cells to ARV-825-and OTX015-induced apoptosis. It is notable that compared with SET2, UKE1 cells are also endogenously less sensitive to ruxolitinib-induced apoptosis. 25 We next determined the apoptotic effects of ARV-825 versus OTX015 against CD34+ sAML cells procured from the bone marrow aspirates and/or peripheral blood of five patients with post-MPN sAML. As demonstrated in Figure 2c , again ARV-825 treatment dose-dependently induced more lethality than OTX015 in the PD CD34+ sAML cells. Notably, both ARV-825 and OTX015 induced relatively less apoptosis in the PD CD34+ sAML as compared with the cultured sAML cell types above. However, ARV-825 and OTX015 were significantly less effective in inducing apoptosis of the normal CD34+ cord blood-derived progenitors, as compared with the PD CD34+ sAML cells, indicating that the PROTAC and BETi exert in vitro selectivity against sAML cells ( Figure 2c ).
Compared to BETi treatment, BET-PROTAC induces more profound perturbation in mRNA transcript levels in sAML cells Utilizing RNA-Seq analysis, we compared the transcriptome changes induced by treatment with ARV-825 with those induced by OTX015 in the cultured sAML SET2 cells. Samples shown represent and were processed as biologic triplicates. Differential gene expression analysis showed that a larger number of genes were up-or downregulated by the in vitro treatment of SET2 cells with ARV-825 compared with treatment with OTX015 ( Figure 3a ), at the same significance threshold. We also noted that for key oncogenes greater mRNA perturbations were induced by ARV--825, as tabulated in Figure 3b . Interestingly, some mRNA expressions such as MYC, PIM1 and Bcl2L1/Bcl-xL (Figure 3b ), were downregulated more by ARV-825 than OTX015, whereas the mRNA of BCL2 and LMO2 were downregulated approximately to a similar extent following treatment with ARV-825 or OTX015 The remaining cells were washed three times in serum-free RPMI-1640 media to remove the drug (drug washout) and re-plated in complete media containing no drug for an additional 24 h. Following this, the total cell lysates were prepared and immunoblot analyses were conducted as indicated. The expression levels of β-actin in the cell lysates served as the loading control. (c) SET2 cells were treated with the indicated concentrations of ARV-825 or OTX015 for 16 h. Then, the cells were cytospun onto glass slides and immunostained for BRD4 expression. The cells were counterstained with DAPI and images were acquired utilizing confocal microscopy. Original magnification is × 100. (Supplementary Figure S2 ). LMO2 gene expression has been previously shown to be upregulated in advanced MPN and sAML cells. 36 In contrast, the mRNA levels of p21 were more upregulated by ARV-825 than OTX015, whereas β-catenin and HEXIM1 were induced to a similar level (Figure 3b and Supplementary Figure S2 ). HEXIM1 induction has been mechanistically linked to BETi-induced growth inhibition and apoptosis, 37 whereas Wnt/β-catenin induction has been shown to be an adaptive resistance mechanism in AML cells following treatment with BETi. 38, 39 The Venn diagram in Figure 3c shows that there was a significant overlap in the gene expressions that were up-or downregulated, following treatment with ARV-825 and OTX015. Gene set enrichment analyses comparing the mRNA signature of ARV-825 and OTX015-treated SET2 cells with REACTOME pathways showed positively and negatively enriched pathways, which are presented in the tables in Supplementary Figures S3 and S4 as the normalized enrichment score for each pathway in the ARV-825and OTX015-treated cells (all q-values are less than 0.25). As an example, the gene set enrichment analyses plot comparing the ARV-825-or OTX015-treated SET2 cells against the gene signature REACTOME pathway for RNA Pol II transcription showed that the q-values for association were lower for ARV-825 ( Supplementary  Figures S3B and C) . Notably, qPCR analyses confirmed that compared with OTX015, treatment with ARV-825 reduced MYC, PIM and BCL2 and increased p21 mRNA expressions to a greater extent than OTX015 (Figure 3d ). In contrast, HEXIM mRNA was induced more by OTX015 treatment. We also performed RNA-Seq and qPCR analyses, following treatment of PD CD34+ sAML cells with ARV-825 versus OTX015. ARV-825 treatment reduced MYC, IL7R, CDK6, LMO2, BCL2 and Bcl2L1/Bcl-xL, but induced p21 and CTNNB1 (β-catenin) mRNA levels to a greater extent than OTX015 in the PD CD34+ sAML cells ( Supplementary Figures S5A-E ). In PD CD34+ sAML cells, there was also a significant overlap in the gene expressions that were up-or downregulated, following treatment with ARV-825 and OTX015 (Supplementary Figure S5C ). Similar effects on the expression of MYC, BCL2, Bcl2L1/Bcl-xL, p21 and HEXIM1 were observed by qPCR analyses in additional PD CD34+ sAML samples ( Supplementary Figures S5F and G) .
Treatment of sAML cells with ARV-825 leads to more extensive protein-level perturbation compared to treatment with OTX015 We also determined the effects of ARV-825 versus OTX015 treatment on protein expressions, utilizing specific and validated antibodies coupled to a reverse-phase protein array. 25, 33 The heat maps in Supplementary Figures S6A and B show the changes in expression (in triplicate) of those proteins that exhibited a ⩾ 1.25fold increase or decrease in their expression and P o 0.05 (relative to the untreated cells) following treatment of SET2 cells with either 250 nm of ARV-825 or OTX015 for 18 h, respectively. As expected, ARV-825 depleted BRD4 levels and OTX015 induced the levels of BRD4. In addition, ARV-825 treatment down-and upregulated more proteins than OTX015 (Supplementary Tables 1  and 2 ). ARV-825 treatment also markedly downregulated pS6, p-STAT3, CHK1, p-Rb (surrogate for CDK4/6 downregulation) JAK2, c-Myc and FOXM1, whereas the protein levels of DNA damageassociated γ-H2AX (H2AX pS140) as well as of cleaved caspase 3 and 7 were upregulated by both ARV-825 and OTX015 ( Supplementary Figures S6A and B ; Supplementary Tables 1 and 2) . Western analyses were conducted to further confirm the effects of ARV-825 versus OTX015 on the protein levels in the sAML SET2 cells. In comparison with OTX015, exposure to ARV-825 caused greater reduction in the levels of JAK2, p-STAT5, STAT5, p-STAT3, STAT3, c-Myc, PIM1, CDK6 and Bcl-xL (Figure 4a ). Both ARV-825 and OTX015 treatment induced the protein expressions of HEXIM1, p27, p21 and γ-H2AX (Figure 4a ). The latter represents increased DNA damage response due to loss of BRD4 function in the ARV-825 or OTX015-treated cells. 40 In addition, co-treatment with pomalidomide restored ARV-825-mediated depletion in the levels of c-Myc, PIM1, Bcl-xL and CDK4 levels, but reduced ARV-825-induced p21 levels in SET2 cells (Supplementary Figure S7A ). This was associated with pomalidomide-mediated inhibition of ARV-825-induced apoptosis of SET2 cells (Supplementary Figure S7B ). To determine whether treatment with ARV-825 has a lasting effect on the protein levels, following treatment of SET2 cells with equimolar concentrations of ARV-825 or OTX015 for 24 h; cells were washed thrice with drug-free medium and incubated in media without drug for an additional 24 h. Western analysis performed on the cell lysates following this incubation demonstrated that ARV-825-mediated depletions in the levels of c-Myc, PIM1, CDK4/6, JAK2 and Bcl-xL were sustained (Figure 4b) . In contrast, after treatment with OTX015, incubation in the drug-free medium restored their levels, indicating a lack of sustained inhibition by OTX015 on the levels of BRD4 and of c-Myc, PIM1, CDK4/6, JAK2 and Bcl-xL (Figure 4b ). Utilizing a recently described mass cytometry approach, we next determined the effects of an equimolar concentration of ARV-825 versus OTX015 on the PD CD34+ sAML cells that were immunophenotypically characterized as early stem/progenitor cells. 34, 35 A bioinformatics algorithm, SPADE (Spanning-tree Progression Analysis of Density-normalized Events; http://pengqiu.gatech.edu/ software/SPADE/), was utilized on the mass cytometry data, using four cell surface markers, to define the cluster that represented the stem/progenitor cells, based on high expression of CD123, CD244, Figure S8A ). 41 As compared with the untreated control, ARV-825 treatment more potently reduced the expression of BRD4, c-Myc and p-Rb while inducing the levels of p21 in the sAML stem/progenitor cells (Supplementary Figure S8B) .
TIM3Fc+ and CD90 (Supplementary
BET-PROTAC ARV-771 is more potent than BETi OTX015 in reducing the in vivo sAML burden and improving survival of NSG mice engrafted with luciferase-transduced sAML cells Following engraftment of luciferase-transduced sAML HEL92.1.7 cells into pre-irradiated NSG mice, we also compared the effects of treatment with ARV-771, a novel BET-PROTAC with superior in vivo pharmacology that recruits the E3 ligase VHL (Von Hippel-Lindau) to degrade BETPs, versus OTX015 or vehicle control on the sAML burden and survival of the mice. Figures 5a and b demonstrate that treatment with ARV-771 was more effective than OTX015 in reducing the bioluminescence in the NSG mice due to the sAML cells, as determined 7 days after engraftment of the sAML cells. Notably, compared with treatment with OTX015, ARV-771 was significantly more effective in improving the median survival of the NSG mice, as depicted in the Kaplan-Meier plot in Figure 5c (P o 0.05). Although treatment with OTX015 appreciably reduced the weight of the NSG mice, treatment with ARV-771 had an insignificant effect on their weight (P = 0.16; Supplementary  Figure S9 ).
Co-treatment with BET-PROTAC and ruxolitinib exerts synergistic lethality in cultured and PD CD34+ sAML cells Next, we determined the activity of co-treatment with ARV-825 and JAKi ruxolitinib against cultured SET2, HEL92.1.7 and PD CD34+ sAML cells expressing JAK2-V617F mutation. Figure 6a demonstrates that co-treatment with ARV-825 and ruxolitinib synergistically induced apoptosis of SET2, with combination indices below 1.0, utilizing the isobologram analyses (Dose and fraction tables presented in Supplementary FigureS S10A  and B ). 42 As compared with treatment with each agent alone, co-treatment with ARV-825 and ruxolitinib caused greater attenuation of p-STAT5, c-Myc, CDK4/6, PIM1 and Bcl-xL in SET2 cells (Figure 6b ). Similar synergy between ARV-825 and ruxolitinib was observed in six samples of PD CD34+ sAML cells (Figure 6c ; dose and fraction tables presented in Supplementary  Figures S10C-H) .
BET-PROTAC exerts lethality against in vitro generated ruxolitinibpersister and ruxolitinib-resistant cells
We had previously reported the isolation and characterization of JAKi-resistant (HEL/JIR) cells. 9 Unlike the parental HEL92.1.7, the HEL/JIR cells were relatively resistant to JAKi-induced apoptosis. It is notable that as compared with HEL92.1.7, UKE1 cells were endogenously less sensitive to ruxolitinib-induced apoptosis. 25 As previously reported for EGFRi-resistant persisters, 43 we also developed ex vivo ruxolitinib-persister cells (HEL/Rux Persister), following repeated weekly exposure (1.0 μm for 48 h) and recovery of the surviving HEL92.1.7 cells. 25 Figure 7a demonstrates that 48 h exposure to ARV-825 dose-dependently induced apoptosis of not only the HEL92.1.7 cells, but also of the HEL/ Rux-persister and HEL/Rux-resistant cells, although the latter cells are slightly less sensitive to higher levels of ARV-825. Treatment with 500 nm of ARV-825 also attenuated the protein levels of BRD4, JAK2, p-STAT5, c-Myc, PIM1, CDK6, while simultaneously inducing the levels of BIM and cleaved PARP (Figure 7b ). These findings highlight that unlike ruxolitinib, ARV-825 retains lethal activity against HEL/Rux-persister and HEL/Rux-resistant cells, as well as against sAML UKE1 cells that are relatively resistant to ruxolitinib. 25 
DISCUSSION
In the present studies, we demonstrate unequivocally that, unlike treatment with BETi OTX015, which leads to intracellular and nuclear accumulation of BRD4 and BRD2, the BET-PROTAC ARV-825 treatment causes more profound and sustained depletion of the levels of BRD4 and BRD2 in the cultured and PD CD34+ sAML progenitor cells. Concomitantly, ARV-825 exerts significantly greater lethality against the cultured or PD CD34+ sAML cells, including those expressing JAK2-V617F and mutant TP53, as compared with the normal CD34+ progenitor cells. As a transcriptional co-regulator, BRD4 recognizes and binds to the acetylated lysine residues on histone proteins and transcription factors at the enhancers and promoters of target genes. 14, 15, 24 Recent studies have demonstrated that, in AML cells, hematopoietic transcription factors recruit BRD4 especially to the nucleosome-free clustered enhancers and to the promoters flanked by acetylated histones. 19, 44, 45 This co-occupancy is facilitated by the activity of the lysine acetyltransferase p300/ CBP, which mediates the lysine acetylation of transcription factors and histone proteins. 15, 19 BRD4 has also been demonstrated to bind through its ET domain to non-acetylated transcription factors, 15, 19 the short form of the lysine methyl transferase NSD3, 46 and to the mediator protein complex, 15, 47 whereas the C-terminal domain of BRD4 binds to P-TEFb. 14, 15 BRD4 recruits these transcriptional co-regulators to the enhancers, which are known to loop over and make stable contact with the promoters to facilitate RNAP2-mediated mRNA transcript elongation. 48 Therefore, ARV-825-mediated depletion of BRD4 is likely to more Figure 5 . BET-PROTAC ARV-771 is more potent than BETi OTX015 in reducing the in vivo sAML burden and improving survival of NSG mice engrafted with luciferase-transduced sAML cells. (a) NSG mice were implanted with luciferase-expressing HEL92.1.7 cells and monitored for 4 days. Mice were imaged to document engraftment of leukemia and then treated with vehicle, OTX015 or ARV-771 as indicated for 1 week. At the end of treatment, the mice were imaged with a Xenogen camera and total photon counts were recorded. (b) Total photon counts in mice treated for 1 week with vehicle, OTX015 or ARV-771 as determined by bioluminescent imaging. * indicates total photon counts that were significantly less in the OTX015 and ARV-771-treated mice compared with the vehicle-treated mice (P o0.05). (c) Kaplan-Meier plot of the in vivo activity of OTX015 or ARV-771 against sAML HEL92.1.7 xenografts in NSG mice. Significance between OTX015 and ARV-771-treated versus vehicle-treated mice was determined by a Mantel-Cox Rank Sum test. P-values less than 0.05 were considered to be significant.
profoundly disrupt the functions of the bound co-regulators than treatment with BETis, including the potential eviction of the mediator complex and P-TEFb, resulting in greater attenuation of the clustered enhancers-driven transcription of the sAML-relevant oncogenes, for example, c-Myc, Bcl-xL, CDK6 and PIM1. 19, 20, 47, 49 One of the most BRD4-occupied loci in AML is the cluster of five enhancers (super enhancer) of MYC that is located 1.8 mega-bases downstream of the promoter of c-Myc; all residing in a single large DNA TAD (topologically associated domain). 19, 47, 48 Indeed, ARV-825 is more effective than OTX015 in reducing the levels of c-Myc in the cultured SET2 and PD CD34+ sAML cells. The serinethreonine kinase PIM1 is involved in phosphorylating and affecting the levels and/or activity of its target proteins, which include c-Myc, p21, p27, BAD and PRAS40. 50, 51 PIM1 and c-Myc cooperate and synergistically increase cell growth, cellular biomass and survival. 50, 51 Therefore, as demonstrated here, ARV-825-mediated simultaneous and greater depletion of PIM1 and c-Myc, as compared with OTX015, may also contribute to the greater induction of p21 and p27, as well as cause higher ARV-825induced lethality in sAML cells. Mutations in JAK2, c-MPL or CALR constitutively activate JAK-STAT signaling, as well as promote survival and proliferation of MPN and sAML progenitor cells. 2, 3, 10 Our findings also demonstrate that, compared with OTX015, treatment with ARV-825 causes greater depletion of JAK2, p-STAT3 and p-STAT5 levels, as well as of BCL2 and Bcl-xL, which further likely contributes to the higher lethal activity of ARV-825 in sAML cells. Treatment with both ARV-825 and OTX015 increased the expression of HEXIM1 and p21, of which p21 is known to be repressed by Myc. 52, 53 Induction of HEXIM1 levels may also have a mechanistic role in inhibiting P-TEFb-mediated RNAP2 activity and the expression of AML-relevant oncogenes. 17, 37 Upregulation of BIM is also explained by ARV-825-induced Myc repression, since Myc induces miR-17-92, which inhibits BIM expression. 53 Utilizing mass cytometry coupled to SPADE algorithm clustering of the data, 34, 35, 41 we also demonstrate for the first time that, compared with OTX015, treatment with ARV-825 caused marked attenuation of BRD4, c-Myc and p-Rb, while inducing more p21 in the CD34+ stem/progenitor cells.
Although inducing significant clinical benefit and improving the survival of patients with advanced post-MPN or primary MF, the JAKi ruxolitinib has modest and short-term clinical efficacy in patients with sAML. 3, 7, 8 This may be due to a lack of efficacy of ruxolitinib alone against sAML stem/progenitor cells. In contrast, findings presented here show that co-treatment with ARV-825 and ruxolitinib exerted synergistic lethality against cultured and PD CD34+ sAML cells. This may be at least partially explained by the observation that, as compared with treatment with each agent alone, co-treatment with ARV-825 and ruxolitinib caused greater attenuation of the levels of p-STAT5, c-Myc, CDK4, PIM1 and Bcl-xL in sAML cells. In post-MPN-MF and sAML, resistance to ruxolitinib has been attributed to persistent JAK-STAT signaling due to transphosphorylation of JAK2 by either JAK1 or TYK2. 11 Additional mechanisms of therapy-resistance in the post-MPN sAML stem/ progenitor cells may be due to the co-occurring mutant TP53 and/ or mutations in several of the chromatin-modifying enzymes, including TET2, EZH2, ASXL1, IDH1/2. 3, 12, 13 We hypothesized that the deregulated transcriptome due to these mutations would likely confer ruxolitinib-resistance in sAML cells. As the deregulated transcriptome would still be BRD4-dependent, it would be undermined by treatment with ARV-825, thereby sensitizing ruxolitinib-resistant sAML cells to ARV-825. Indeed, our findings demonstrate that ARV-825 exerted lethality against ruxolitinibpersister/resistant sAML cells that also express mutant TP53 (Figure 7 ). Recent reports have demonstrated that in MLL-AF9driven mouse AML and in human AML cells, resistance to BETi is not mediated through increased drug-efflux or metabolism but is, at least in part, due to increased activity of WNT-beta-catenin/ TCF4 and the restoration of c-Myc expression, despite inhibition of chromatin-bound BRD4. 38, 39 BETi resistance was also shown to emerge from leukemia stem cells both ex vivo and in vivo. 38, 39 Although findings presented here demonstrate that treatment with ARV-825 transcriptionally induced the expression of CTNNB1 (β-catenin) in sAML cells, this did not compromise ARV-825mediated depletion of c-Myc or affect ARV-825-induced lethality in sAML cells.
ARV-771 is a novel BET-PROTAC that recruits the E3 ligase VHL (Von Hippel-Lindau) to degrade BETPs, including BRD4 and BRD2. ARV-771 displays not only superior in vitro lethal effects but also exhibits superior in vivo pharmacology and was shown to exert antitumor efficacy when administered subcutaneously in tumorbearing mice. 54 Our findings presented here clearly demonstrate for the first time a potent and superior anti-leukemia effect of ARV-771 compared with OTX015 in reducing the sAML burden in the NSG mice engrafted with the sAML HEL92.1.7 cells. This translated into a significantly improved survival of the NSG mice treated with ARV-771 versus OTX015, associated with greater tolerability for ARV-771. These findings strongly support future studies interrogating the in vivo efficacy of ARV-771 versus BETi, alone and in combination with ruxolitinib or other targeted therapies, utilizing PD xenograft (PDX) models of sAML cells engrafted in immune-depleted mice.
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